{
    "clinical_study": {
        "@rank": "85694", 
        "acronym": "CLUBNET-CABAZ", 
        "arm_group": {
            "arm_group_label": "Cabazitaxel chemotherapy", 
            "arm_group_type": "Other", 
            "description": "Patients undergo 6 cycles Cabazitaxel chemotherapy. Cabazitaxel suspension is given once per cycle as infusion intravenously, 1 mg/square meter.\nFor max. 6 times at all."
        }, 
        "brief_summary": {
            "textblock": "This study is aimed at evaluating the efficacy regarding the response rate and\n      metastasis-free survival time of cabazitaxel as a neoadjuvant treatment in patients with\n      high risk prostate cancer."
        }, 
        "brief_title": "CLUBNET-CABAZ_L_06639 Neoadjuvant Chemotherapy With Cabazitaxel", 
        "completion_date": {
            "#text": "August 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "High-Risk Cancer", 
        "detailed_description": {
            "textblock": "Patients will be treated by 6 cycles of Cabazitaxel 25 mg/m2 every three weeks and extended\n      radical prostatectomy and extended pelvic lymphadenectomy 4 weeks after completion of\n      chemotherapy. Multiparametric MRI will be performed at baseline, after 3 cycles and after 6\n      cycles. If there will be evidence of clinical progression after 3rd cycle, patients can be\n      removed from the study and given local therapy, including radical prostatectomy or external\n      beam radiotherapy, at the discretion of the patient's physicians. If patients have evidence\n      of response, they continue on treatment for a total of 6 cycles. If multiparametric MRI\n      demonstrates stable disease an individual risk-benefit analysis has to be performed with\n      regard to continuing or to stopping the neoadjuvant treatment since the definition stable\n      disease includes patients with \u2264 20% tumour shrinkage or tumour progression"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Surgically resectable high risk prostate cancer with a 5-year relapse probability \u2265\n             60% according to the Kattan pre-operative nomogram (cancer 2009, 115: 1005-1010)\n\n               -  no prior therapy for prostate cancer such as androgen deprivation therapy,\n                  radiation therapy, or chemotherapy\n\n               -  ECOG performance status 0-1\n\n          -  No evidence of active infection\n\n               -  Hemoglobin >9.0 g/dL\n\n               -  Absolute neutrophil count >1.5 x 109/L,\n\n               -  Platelet count >100 x 109/L,\n\n               -  AST/SGOT and/or ALT/SGPT <2.5 x ULN;\n\n               -  Total bilirubin <1.0 x ULN,\n\n               -  Serum creatinine <1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance\n                  will be calculated according to CKD-EPI formula and patients with creatinine\n                  clearance <60 mL/min should be excluded)\n\n               -  Patient information and signature of informed consent\n\n               -  Male \u2265 18 years\n\n               -  Patients of reproductive age must take appropriate contraceptive precautions\n                  during and for 6 months after the end of their participation in the study\n\n        Exclusion Criteria:\n\n          -  Evidence of lymph node, visceral or bone metastases\n\n               -  previous major intrapelvic surgery\n\n               -  previous radiation therapy to the small pelvis\n\n               -  any type of malignancies within the last 5 years except basalioma and non-muscle\n                  invasive urothelial cancer of the urinary bladder\n\n               -  previous chemotherapy with taxanes (docetaxel, paclitaxel, cabazitaxel) for any\n                  indication\n\n               -  Hypersensitivity to the active substance or to any of the excipients\n\n               -  Known or suspected brain metastases or leptomeningeal metastases\n\n               -  Active or symptomatic viral hepatitis or chronic liver disease\n\n               -  Serious or uncontrolled co-existent non-malignant disease, including active and\n                  uncontrolled infection"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941550", 
            "org_study_id": "13-005"
        }, 
        "intervention": {
            "arm_group_label": "Cabazitaxel chemotherapy", 
            "description": "given in 6 cycles", 
            "intervention_name": "Cabazitaxel chemotherapy", 
            "intervention_type": "Drug", 
            "other_name": "Jevtana L01CD04"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "untreated, high risk prostate cancer", 
        "lastchanged_date": "September 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Aachen", 
                    "country": "Germany", 
                    "state": "North Rhine Westfalia", 
                    "zip": "52074"
                }, 
                "name": "University Hospital Aachen"
            }, 
            "investigator": {
                "last_name": "David Pfister, Dr. med.", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Neoadjuvant Chemotherapy With Cabazitaxel in High Risk Prostate Cancer Patients Prior to Radical Prostatectomy", 
        "overall_contact": {
            "email": "aheidenreich@ukaachen.de", 
            "last_name": "Axel Heidenreich, Prof. Dr. med.", 
            "phone": "+49 241 8089374"
        }, 
        "overall_official": {
            "affiliation": "Department of Urology", 
            "last_name": "Axel Heidenreich, Prof. Dr.med.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ministry of Work, Health and Social Affairs in North Rhine-Westph", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary endpoint: overall or cancer specific survival nor progression-free survival(PFS) in 5 years. Composite measurement.\nKey-parameters:\nComplete pathohistological remission\nIntra/perioperative compl.\nPFS\nMetastasis-FS\nBiochemical, radiological, clinical PFS and androgen-deprivation FS\nObjective progr. during cabazitaxel therapy (cab.th.) and post surgery\nPSA response at the end of cab.th.\nPSA progression after 12 w. of cab.th.\nPercentage of pat. with undetectable PSA (<0.1 ng/ml) post surgery\nRelationship between PSA kinetics, histol. response and MRI response\nRole of pathohistol. parameters such as intraductal, cribriform growth patterns and effect on response\nImmunohistochemical evaluation of prostate biopsy and radical prostatectomy specimens of markers potentially associated with chemoresistance: growth differentiation factor 15, surviving, beta-tubuline I & II, p53, bcl-2,\nMeasurement of the serum concentrations of free circulating mDNA", 
            "measure": "Complete pathological response rate", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941550"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "RWTH Aachen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "RWTH Aachen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}